Arjola Bano1, Layal Chaker1, Francesco U S Mattace-Raso1, Aad van der Lugt1, M Arfan Ikram1, Oscar H Franco1, Robin P Peeters2, Maryam Kavousi1. 1. From the Department of Internal Medicine (A.B., L.C., F.U.S.M.-R., R.P.P.), Academic Center for Thyroid Diseases (A.B., L.C., R.P.P.), Department of Epidemiology (A.B., L.C., M.A.I., O.H.F., R.P.P., M.K.), Section of Geriatric Medicine, Department of Internal Medicine (F.U.S.M.-R.), and Department of Radiology (A.v.d.L.), Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (L.C.). 2. From the Department of Internal Medicine (A.B., L.C., F.U.S.M.-R., R.P.P.), Academic Center for Thyroid Diseases (A.B., L.C., R.P.P.), Department of Epidemiology (A.B., L.C., M.A.I., O.H.F., R.P.P., M.K.), Section of Geriatric Medicine, Department of Internal Medicine (F.U.S.M.-R.), and Department of Radiology (A.v.d.L.), Department of Internal Medicine, Erasmus Medical Center, Rotterdam, The Netherlands; and Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA (L.C.). r.peeters@erasmusmc.nl.
Abstract
RATIONALE: Thyroid hormones have been linked with various proatherogenic and antiatherogenic processes. However, the relationship of thyroid function with manifestations of atherosclerosis remains unclear. OBJECTIVE: To investigate the association of thyroid function with atherosclerosis throughout its spectrum; that is, subclinical atherosclerosis, incident atherosclerotic cardiovascular (ASCV) events, and ASCV mortality. METHODS AND RESULTS: This population-based study was embedded within the Rotterdam Study. The risk of atherosclerosis was evaluated by measuring (1) presence of subclinical atherosclerosis, assessed by coronary artery calcification score >100 AU; (2) ASCV events, defined as fatal and nonfatal myocardial infarction, other coronary heart disease mortality, or stroke; (3) ASCV mortality, defined as death because of coronary heart disease and cerebrovascular or other atherosclerotic diseases. Associations of thyroid-stimulating hormone and free thyroxine with the outcomes were assessed through logistic regression and Cox proportional hazard models, adjusted for potential confounders, including cardiovascular risk factors. A total of 9420 community-dwelling participants (mean age±SD, 64.8±9.7 years) were included. During a median follow-up of 8.8 years (interquartile range, 4.5-11.8 years), 934 incident ASCV events and 612 ASCV deaths occurred. Free thyroxine levels were positively associated with high coronary artery calcification score (odds ratio, 2.28; 95% confidence interval, 1.30-4.02) and incident ASCV events (hazard ratio, 1.87; confidence interval, 1.34-2.59). The risk of ASCV mortality increased in a linear manner with higher free thyroxine levels (hazard ratio, 2.41; confidence interval, 1.68-3.47 per 1 ng/dL) and lower thyroid-stimulating hormone levels (hazard ratio, 0.92; confidence interval, 0.84-1.00 per 1 logTSH). Results remained similar or became stronger among euthyroid participants. CONCLUSIONS: Free thyroxine levels in middle-aged and elderly subjects were positively associated with atherosclerosis throughout the whole disease spectrum, independent of cardiovascular risk factors.
RATIONALE: Thyroid hormones have been linked with various proatherogenic and antiatherogenic processes. However, the relationship of thyroid function with manifestations of atherosclerosis remains unclear. OBJECTIVE: To investigate the association of thyroid function with atherosclerosis throughout its spectrum; that is, subclinical atherosclerosis, incident atherosclerotic cardiovascular (ASCV) events, and ASCV mortality. METHODS AND RESULTS: This population-based study was embedded within the Rotterdam Study. The risk of atherosclerosis was evaluated by measuring (1) presence of subclinical atherosclerosis, assessed by coronary artery calcification score >100 AU; (2) ASCV events, defined as fatal and nonfatal myocardial infarction, other coronary heart disease mortality, or stroke; (3) ASCV mortality, defined as death because of coronary heart disease and cerebrovascular or other atherosclerotic diseases. Associations of thyroid-stimulating hormone and free thyroxine with the outcomes were assessed through logistic regression and Cox proportional hazard models, adjusted for potential confounders, including cardiovascular risk factors. A total of 9420 community-dwelling participants (mean age±SD, 64.8±9.7 years) were included. During a median follow-up of 8.8 years (interquartile range, 4.5-11.8 years), 934 incident ASCV events and 612 ASCVdeaths occurred. Free thyroxine levels were positively associated with high coronary artery calcification score (odds ratio, 2.28; 95% confidence interval, 1.30-4.02) and incident ASCV events (hazard ratio, 1.87; confidence interval, 1.34-2.59). The risk of ASCV mortality increased in a linear manner with higher free thyroxine levels (hazard ratio, 2.41; confidence interval, 1.68-3.47 per 1 ng/dL) and lower thyroid-stimulating hormone levels (hazard ratio, 0.92; confidence interval, 0.84-1.00 per 1 logTSH). Results remained similar or became stronger among euthyroid participants. CONCLUSIONS: Free thyroxine levels in middle-aged and elderly subjects were positively associated with atherosclerosis throughout the whole disease spectrum, independent of cardiovascular risk factors.
Authors: Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson Journal: Thyroid Date: 2019-05-13 Impact factor: 6.568
Authors: Anne R Cappola; Akshay S Desai; Marco Medici; Lawton S Cooper; Debra Egan; George Sopko; Glenn I Fishman; Steven Goldman; David S Cooper; Samia Mora; Peter J Kudenchuk; Anthony N Hollenberg; Cheryl L McDonald; Paul W Ladenson Journal: Circulation Date: 2019-05-13 Impact factor: 29.690
Authors: Eirini Marouli; Aleksander Kus; Fabiola Del Greco M; Layal Chaker; Robin Peeters; Alexander Teumer; Panos Deloukas; Marco Medici Journal: J Clin Endocrinol Metab Date: 2020-08-01 Impact factor: 5.958
Authors: João Sérgio Neves; Ricardo Fontes-Carvalho; Marta Borges-Canha; Ana Rita Leite; Sandra Martins; Ana Oliveira; João Tiago Guimarães; Davide Carvalho; Adelino Leite-Moreira; Ana Azevedo Journal: Eur Thyroid J Date: 2020-07-08
Authors: Nicole Lafontaine; Purdey J Campbell; Juan E Castillo-Fernandez; Shelby Mullin; Ee Mun Lim; Phillip Kendrew; Michelle Lewer; Suzanne J Brown; Rae-Chi Huang; Phillip E Melton; Trevor A Mori; Lawrence J Beilin; Frank Dudbridge; Tim D Spector; Margaret J Wright; Nicholas G Martin; Allan F McRae; Vijay Panicker; Gu Zhu; John P Walsh; Jordana T Bell; Scott G Wilson Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: Maria Papaleontiou; Deborah A Levine; David Reyes-Gastelum; Sarah T Hawley; Mousumi Banerjee; Megan R Haymart Journal: J Clin Endocrinol Metab Date: 2021-09-27 Impact factor: 6.134